RxDoctor Payments Data

Kaitlin Baron, MD

Cardiovascular Disease · Silver Spring, MDNPI 1942576921

Payments from drug & device makers

$3,760in general payments, 2019–2025

Across 187 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$707
  • Novartis$530
  • Merck$279
  • Pfizer$261
  • Johnson & Johnson$259
  • AstraZeneca$171
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,69398%
  • Other$672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,760 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$430,269
Medicare patients
1,287
Services billed
4,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban245$357,239
XareltoRivaroxaban54$65,138
EntrestoSacubitril/Valsartan34$45,624
JardianceEmpagliflozin15$23,941
BrilintaTicagrelor27$20,163
Metoprolol Succinate259$5,426
Rosuvastatin Calcium113$2,750
Atorvastatin Calcium219$2,509
Bumetanide49$2,274
Ezetimibe25$1,938
Candesartan Cilexetil15$1,762
Carvedilol133$1,290
Tiadylt ErDiltiazem Hcl24$1,189
Amiodarone Hcl31$1,140
Amlodipine Besylate128$1,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$261$357,239245 claims
Johnson & JohnsonXarelto$259$65,13854 claims
NovartisEntresto$530$45,62434 claims
Boehringer IngelheimJardiance$169$23,94115 claims
AstraZenecaBrilinta$171$20,16327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →